This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies.Continue
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine.
This PIL is in PDF format and so you must have a PDF reader installed on your device to read it.
Text only version for the visually impaired
Below is a text only representation of the Patient Information leaflet. The original may contain images or tables and can be viewed in PDF format using the link above. This PIL may be available from the RNIB in large print, Braille or audio CD. For further information please call the RNIB Medicine Leaflet line on 0800 198 5000. The product code(s) for this leaflet is/are: EU/1/07/391/002, EU/1/07/391/003, EU/1/07/391/004, EU/1/07/391/001, EU/1/07/391/006, EU/1/07/391/009.
Revlimid 2.5 mg 5mg 7.5mg 10mg 15mg 20mg 25mg hard capsules
Package leaflet: Information for the patient
Revlimid 2.5 mg hard capsules
Revlimid 5 mg hard capsules
Revlimid 7.5 mg hard capsules
Revlimid 10 mg hard capsules
Revlimid 15 mg hard capsules
Revlimid 20 mg hard capsules
Revlimid 25 mg hard capsules
lenalidomide
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Revlimid is and what it is used for
2. What you need to know before you take Revlimid
3. How to take Revlimid
4. Possible side effects
5. How to store Revlimid
6. Contents of the pack and other information
1. What Revlimid is and what it is used for
What Revlimid is
Revlimid contains the active substance ‘lenalidomide’. This medicine belongs to a group of medicines which affect how your immune system works.
What Revlimid is used for
Revlimid is used in adults for:
1. Multiple myeloma
2. Myelodysplastic syndromes (MDS)
3. Mantle cell lymphoma (MCL)
Multiple myeloma
Multiple myeloma is a type of cancer which affects a certain kind of white blood cell, called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys.
Multiple myeloma generally cannot be cured. However, the signs and symptoms can be greatly reduced or disappear for a period of time. This is called a ‘response’.
Newly diagnosed multiple myeloma – in patients who have had a bone marrow transplant
Revlimid is used on its own as maintenance therapy after patients have recovered enough following a bone marrow transplant.
Newly diagnosed multiple myeloma – in patients who cannot have a bone marrow transplant
Revlimid is taken with other medicines:
You will take these other medicines at the start of treatment and then continue to take Revlimid on its own.
If you are aged 75 years or older or have moderate to severe kidney problems - your doctor will check you carefully before starting treatment.
Multiple myeloma – in patients who have had treatment before
Revlimid is taken together with an anti-inflammatory medicine called ‘dexamethasone’.
Revlimid can stop the signs and symptoms of multiple myeloma getting worse. It has also been shown to delay multiple myeloma from coming back following treatment.
Myelodysplastic syndromes
MDS are a collection of many different blood and bone marrow diseases. The blood cells become abnormal and do not function properly. Patients can experience a variety of signs and symptoms including a low red blood cell count (anemia), the need for a blood transfusion, and be at risk of infection.
Revlimid is used alone to treat adult patients who have been diagnosed with MDS, when all of the following apply:
Revlimid can increase the number of healthy red blood cells that the body produces by reducing the number of abnormal cells:
Mantle cell lymphoma
MCL is a cancer of part of the immune system (the lymph tissue). It affects a type of white blood cell called ‘B-lymphocytes’ or B-cells. MCL is a disease where B-cells grow in an uncontrolled way and build up in the lymph tissue, bone marrow or blood.
Revlimid is used alone to treat adult patients who have previously been treated with other medicines.
How Revlimid works
Revlimid works by affecting the body’s immune system and directly attacking the cancer. It works in a number of different ways:
2. What you need to know before you take Revlimid
Do not take Revlimid:
If any of these apply to you, do not take Revlimid. Talk to your doctor if you are not sure.
Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Revlimid if:
If any of the above apply to you, tell your doctor before starting treatment.
If you have MDS, you may be more likely to get a more advanced condition called acute myeloid leukaemia (AML). In addition, it is not known how Revlimid affects the chances of you getting AML. Your doctor may therefore do tests to check for signs which may better predict the likelihood of you getting AML during your treatment with Revlimid.
Tests and checks
Before and during the treatment with Revlimid you will have regular blood tests as Revlimid may cause a fall in the blood cells that help fight infection (white blood cells) and help the blood to clot (platelets).
Your doctor will ask you to have a blood test:
For patients with MCL taking Revlimid
Your doctor will ask you to have a blood test:
Your doctor may check if you have a high total amount of tumour throughout the body, including your bone marrow. This could lead to a condition where the tumours break down and cause unusual levels of chemicals in the blood which can lead to kidney failure (this condition is called ‘Tumour Lysis Syndrome’).
Your doctor may check you for changes to your skin such as red spots or rashes.
Your doctor may adjust your dose of Revlimid or stop your treatment based on the results of your blood tests and on your general condition. If you are newly diagnosed, your doctor may also assess your treatment based on your age and other conditions you already have.
Blood donation
You should not donate blood during treatment and for 1 week after the end of treatment.
Children and adolescents
Revlimid is not recommended for use in children and adolescents under 18 years.
Elderly and people with kidney problems
If you are aged 75 years or older or have moderate to severe kidney problems - your doctor will check you carefully before starting treatment.
Other medicines and Revlimid
Tell your doctor or nurse if you are taking or have recently taken any other medicines. This is because Revlimid can affect the way some other medicines work. Also, some other medicines can affect the way Revlimid works.
In particular, tell your doctor or nurse if you are taking any of the following medicines:
Pregnancy, breast-feeding and contraception - information for women and men
Pregnancy
For women taking Revlimid
For men taking Revlimid
Breast-feeding
You must not breast-feed when taking Revlimid, as it is not known if Revlimid passes into human milk.
Contraception
For women taking Revlimid
Before starting the treatment, ask your doctor if you are able to become pregnant, even if you think this is unlikely.
If you are able to become pregnant
AND
For men taking Revlimid
Revlimid passes into human semen. If your female partner is pregnant or able to become pregnant, and she does not use effective methods of contraception, you must use condoms during treatment and 1 week after the end of treatment, even if you have had a vasectomy.
Driving and using machines
Do not drive or operate machines if you feel dizzy, tired, sleepy, have vertigo or blurred vision after taking Revlimid.
Revlimid contains lactose
Revlimid contains lactose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.
3. How to take Revlimid
Revlimid must be given to you by healthcare professionals with experience in treating multiple myeloma, MDS or MCL.
Always take Revlimid exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
If you are taking Revlimid in combination with other medicines, you should refer to the package leaflets for these medicines for further information on their use and effects.
Treatment cycle
Revlimid is taken on certain days over 4 weeks (28 days).
How much Revlimid to take
Before you start treatment, your doctor will tell you:
How and when to take Revlimid
Taking this medicine
To remove the capsule from the blister:
Duration of the treatment with Revlimid
Revlimid is taken in treatment cycles, each cycle lasting 28 days (see above ‘Treatment cycle’). You should continue the cycles of treatment until your doctor tells you to stop.
If you take more Revlimid than you should
If you take more Revlimid than was prescribed, tell your doctor immediately.
If you forget to take Revlimid
If you forget to take Revlimid at your regular time and
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, Revlimid can cause side effects, although not everybody gets them.
Serious side effects which may affect more than 1 in 10 people (very common)
Revlimid may reduce the number of white blood cells that fight infection and also the blood cells which help the blood to clot (platelets) which may lead to bleeding disorders such as nosebleeds and bruising.
Revlimid may also cause blood clots in the veins (thrombosis).
Therefore you must tell your doctor immediately if you experience:
Other side effects
It is important to note that a small number of patients may develop additional types of cancer, and it is possible that this risk may be increased with Revlimid treatment, therefore your doctor should carefully evaluate the benefit and risk when you are prescribed Revlimid.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Not known (frequency cannot be estimated from the available data):
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard (Freephone 0808 100 3352). By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Revlimid
6. Contents of the pack and other information
What Revlimid contains
Revlimid 2.5 mg hard capsules:
Revlimid 5 mg hard capsules:
Revlimid 7.5 mg hard capsules:
Revlimid 10 mg hard capsules:
Revlimid 15 mg hard capsules:
Revlimid 20 mg hard capsules:
Revlimid 25 mg hard capsules:
What Revlimid looks like and contents of the pack
Revlimid 2.5 mg hard capsules are blue-green/white, with ‘REV 2.5 mg’ written on them.
The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.
Revlimid 5 mg hard capsules are white, with ‘REV 5 mg’ written on them.
The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.
Revlimid 7.5 mg hard capsules are pale yellow/white, with ‘REV 7.5 mg’ written on them.
The capsules are provided in packs. Each pack contains three blisters, each blister with seven capsules. This gives a total of 21 capsules per pack.
Revlimid 10 mg hard capsules are blue-green/pale yellow, with ‘REV 10 mg’ written on them.
The capsules are provided in packs. Each pack contains three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.
Revlimid 15 mg hard capsules are pale blue/white, with ‘REV 15 mg’ written on them.
The capsules are provided in packs. Each pack contains three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.
Revlimid 20 mg hard capsules are blue-green/pale blue, with ‘REV 20 mg’ written on them.
The capsules are provided in packs. Each pack contains three blisters, each blister with seven capsules. This gives a total of 21 capsules per pack.
Revlimid 25 mg hard capsules are white, with ‘REV 25 mg’ written on them.
The capsules are provided in packs. Each pack contains three blisters, each blister with seven capsules. This gives a total of 21 capsules per pack.
Marketing Authorisation Holder
Manufacturer
This leaflet was last revised in 02/2017
Other sources of information:
Detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu/.
There are also links to other websites about rare diseases and treatments.